Radiographic progression and disease modifying antirheumatic drug use
| Erosion or JSN | Shortened RCL | Erosion location | Time between x rays (m) | DMARD delay (m) | |
|---|---|---|---|---|---|
| Progression = increase in JSN or number of erosions on subsequent hand/wrist x ray. | |||||
| Erosion or JSN = erosion or joint space narrowing on subsequent hand/wrist x ray. | |||||
| Shortened RCL = RCL on subsequent x ray less than on initial x ray. | |||||
| Erosion location = location of erosions on subsequent x ray (0, no erosions). | |||||
| DMARD delay = time between date of diagnosis of polyJRA and first dose of disease modifying medication (including hydroxychloroquine, sulfasalazine, oral or parenteral gold, methotrexate). | |||||
| C, carpal; DMARD, disease modifying antirheumatic drug; I, proximal or distal interphalangeal, JSN, joint space narrowing; m, months; M, metacarpophalangeal; N, no; N/A, not assessed; RCL, relative carpal length; Y, yes. | |||||
| Subjects with progression | |||||
| 1 | Y | N/A | C, M | 14.6 | 0.0 |
| 2 | Y | Y | C, M | 11.0 | 5.4 |
| 3 | Y | N | 0 | 12.1 | 14.4 |
| 4 | Y | N | M | 20.1 | 14.0 |
| 5 | Y | N | C, M | 22.6 | 9.6 |
| 6 | Y | N/A | C | 24.9 | 0.0 |
| 100% | 25% | Median = 17.4 | Median = 7.5 | ||
| Subjects with no progression | |||||
| 7 | N | N | 0 | 13.3 | 0.0 |
| 8 | N | N | 0 | 8.3 | 8.3 |
| 9 | N | N | 0 | 11.6 | 5.5 |
| 10 | N | N | 0 | 18.2 | 1.6 |
| 11 | N | N | 0 | 11.2 | 1.7 |
| 12 | Y | N/A | C | 19.6 | 0.0 |
| 13 | N | N | 0 | 12.0 | 0.0 |
| 16% | 0% | Median = 12 | Median = 1.6 | ||